Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program.

Community Mental Health Journal
Robert ConstantineRajiv Tandon

Abstract

We studied trends in antipsychotic polypharmacy over a 4 year period in order to see if a change occurred when a statewide quality improvement program aimed at reducing the practice was implemented. Antipsychotic polypharmacy prevalence rates were calculated for eight 6-month periods for enrollees with schizophrenia and schizoaffective disorder and for those with all other diagnoses. Prevalence increased from 1/2003 to 12/2004 and then declined for 4 successive 6 month periods beginning in the 1/2005-6/05 period when the program began. Piecewise linear regression results for both diagnostic groups confirmed that the change in the likelihood of antipsychotic polypharmacy during the four 6 month periods before program implementation were significantly different than during the four 6 month periods following implementation. While it is impossible to control for the effects of all variables in evaluating the impact of any system wide intervention the data suggest that the program did help to reduce the use of antipsychotic polypharmacy.

References

Feb 2, 1999·The British Journal of Psychiatry : the Journal of Mental Science·J L WaddingtonA Kinsella
Jun 5, 2001·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R M ProcyshynB Thompson
Jun 6, 2002·Schizophrenia Bulletin·Alexander L Miller, Catherine S Craig
Apr 29, 2003·The Journal of Clinical Psychiatry·A John RushUNKNOWN TMAP Research Group
Apr 29, 2003·The Journal of Clinical Psychiatry·Trisha SuppesUNKNOWN Texas Medication Algorithm Project
Nov 25, 2003·The Journal of Clinical Psychiatry·Robert E McCueLeonel Urcuyo
Jan 2, 2004·The American Journal of Psychiatry·Dennis S Charney
Feb 27, 2004·The International Journal of Neuropsychopharmacology·Stephen M Stahl
Apr 2, 2004·The American Journal of Psychiatry·Franca CentorrinoRoss J Baldessarini
May 13, 2004·The International Journal of Neuropsychopharmacology·Donald C Goff, Oliver Freudenreich
Jul 17, 2004·British Journal of Clinical Pharmacology·Kang SimChay H Tan
Jan 12, 2005·The Journal of Clinical Psychiatry·Michael J Sernyak, Robert Rosenheck
Sep 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Hiroto ItoTeruhiko Higuchi
Sep 30, 2005·International Clinical Psychopharmacology·Bruno BiancosinoLuigi Grassi
Feb 2, 2006·The British Journal of Psychiatry : the Journal of Mental Science·Matti JoukamaaVille Lehtinen
Apr 25, 2006·Schizophrenia Research·Julie KreyenbuhlFrederic C Blow
Jun 24, 2006·Schizophrenia Research·Hiroaki HoriHiroshi Kunugi
Jul 28, 2006·Psychiatric Services : a Journal of the American Psychiatric Association·Miranda H ChakosRobert A Rosenheck
Oct 3, 2006·International Clinical Psychopharmacology·Corrado BarbuiMichele Tansella
Jul 3, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Todd P GilmerDilip V Jeste
Sep 13, 2007·Current Medical Research and Opinion·Robert J ValuckUNKNOWN Medicaid Pharmacotherapy Research Consortium
Oct 24, 2007·Schizophrenia Research·Soma GanesanRic M Procyshyn
Dec 22, 2007·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Constantin TranulisEmmanuel Stip
Apr 9, 2008·BMC Psychiatry·Baojin ZhuJohn M Kane
May 30, 2008·The Journal of Clinical Psychiatry·Christoph U Correll
Oct 25, 2008·Joint Commission Journal on Quality and Patient Safety·Jessica L GörenRichard C Hermann
Sep 23, 2010·Journal of Environmental Radioactivity·Borys LedoshchukFaina Linkov

❮ Previous
Next ❯

Citations

Apr 12, 2011·CNS Drugs·Thomas R E Barnes, Carol Paton
Mar 26, 2014·Pharmacoepidemiology and Drug Safety·Emily Leckman-WestinMolly Finnerty
Nov 20, 2012·Schizophrenia Research·Hideaki TaniMasaru Mimura
Nov 12, 2017·Community Mental Health Journal·Robert O CotesBenjamin G Druss
Dec 10, 2014·Therapeutic Advances in Psychopharmacology·Anne Connolly, David Taylor
May 20, 2021·Administration and Policy in Mental Health·Marcela Horvitz-LennonSharon-Lise T Normand

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here